Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARK-E021 in mild to moderate acne vulgaris
NCT01494285Phase 2Completed
- Sponsor
- Arkin Holdings
- Start
- Jun 2012
- Primary completion
- Oct 2013
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zilxi in acne vulgaris, sponsored by Arkin Holdings. Started Jun 2012; status: completed.
02
Drugs
zilxi
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT01494285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01494285.